Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have earned an average rating of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation […]
Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have earned an average rating of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation […]
